Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression
Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression
复制标题
甲胎蛋白乙酰化促进肝细胞癌进展
DOI:
10.1016/j.canlet.2019.11.043
复制
发表时间:
2020-02-28
期刊:
影响因子:
9.7
通讯作者:
Zhang, Xiaowei
中科院分区:
文献类型:
--
作者:
Xue, Junhui;Cao, Zhengyi;Zhang, Xiaowei
Alpha-fetoprotein (AFP) is a well-established biomarker for hepatocellular carcinoma (HCC). Here, we investigated the acetylation state of AFP in vivo. AFP acetylation was regulated by the acetyltransferase CBP and the deacetylase SIRT1. Acetylation of AFP at lysines 194, 211, and 242 increased the stability of AFP protein by decreasing its ubiquitination and proteasomal degradation. AFP acetylation promoted its oncogenic role by blocking binding to the phosphatase PTEN and the pro-apoptotic protein caspase-3, which increased signaling for proliferation, migration, and invasion and decreased apoptosis. High levels of acetylated AFP in HCC tissues were associated with HBV infection and correlated with poor prognosis and decreased patient survival. In HCC cells, hepatitis B virus X protein (HBx) and palmitic acid (PA) increased the level of acetylated AFP by disrupting SIRT1-mediated deacetylation. AFP acetylation plays an important role in HCC progression and provides a new potential prognostic marker and therapeutic target for HCC.